Is Viking Therapeutics Stock a No-Brainer Buy Below $35?

Viking Therapeutics is running phase 3 trials for lead obesity drug VK2735, with data expected next year and a potential start to late-stage studies for an oral formulation by year-end. The article frames the stock as a high-risk, catalyst-driven name: strong phase 2/3 results could drive significant upside, while setbacks could erase value over the next five years. Shares are down 8% year to date and currently trade around $32.

Analysis

VKTX is still a binary-duration trade rather than a clean fundamentals story: the next 6-18 months are dominated by readout risk, label-risk, and competitive positioning versus better-capitalized obesity incumbents. The market is implicitly valuing VKTX as if phase 3 can re-rate the asset, but in obesity the punishment for any efficacy, tolerability, or discontinuation miss is immediate because investors can now compare across multiple late-stage datasets in real time. The key second-order issue is that even “good” data may not be enough if it looks merely competitive instead of clearly superior on durability, GI tolerability, or convenience.

The most interesting asymmetry is in the oral program. If the injectable is the base case and the oral becomes the upside call option, the company could create a two-step rerating path: first on proof of concept in phase 3, then on a differentiated administration profile that expands prescriber adoption and payer flexibility. That said, oral obesity drugs are where the market’s bar is highest; any signal that exposure-response is weaker than the injectable will compress the valuation multiple faster than the headline efficacy can expand it.

From a trading perspective, the stock is likely to remain headline-sensitive for months, but the real inflection is concentrated around the next major clinical milestones rather than day-to-day tape. The contrarian view is that consensus may still be underappreciating how much of the obesity opportunity is already crowded into winner-take-most assumptions; if VKTX lands as merely ‘another good GLP-1/GIP name,’ the stock can underperform despite positive data. Conversely, because the starting valuation is low enough relative to peak-market narratives, a clean de-risking event could force systematic and event-driven buying into a thinly owned name.

Key Decisions for Investors

• Initiate a small starter long in VKTX only into weakness, sized for binary event risk; treat it as a 6-12 month catalyst trade, not a core holding.
• Buy VKTX Jan-2026 upside calls or call spreads to express clinical success while capping downside; prefer spreads to reduce theta bleed ahead of readouts.
• Pair trade: long VKTX vs short a basket of higher-quality obesity winners/adjacent leaders if the goal is relative upside on positive data; this isolates event alpha while limiting sector beta.
• If already long, trim into any pre-data speculative run-up and re-add only after confirmation; implied volatility is likely to overstate the expected move until the actual phase 3 inflection.
• Avoid outright shorting VKTX ahead of catalyst windows unless you can hedge with options; the stock has enough convexity that even modestly favorable data could produce a sharp squeeze.